Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Sep;68(3):594–598. doi: 10.1038/bjc.1993.392

High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours.

M J Barnett 1, C M Coppin 1, N Murray 1, T J Nevill 1, D E Reece 1, H G Klingemann 1, J D Shepherd 1, S H Nantel 1, H J Sutherland 1, G L Phillips 1
PMCID: PMC1968411  PMID: 8394733

Abstract

Twenty-one patients with poor prognosis nonseminomatous germ cell tumours (six with extreme burden disease at presentation in whom partial remission had been achieved with initial induction therapy, and 15 with recurrent disease after induction therapy) were treated with high-dose chemotherapy and autologous bone marrow transplantation (BMT). The first six received etoposide 3.0 g m-2, ifosfamide 6.0 g m-2 and carboplatin 1.2 g m-2 (Regimen 1), and the subsequent 15 received etoposide 2.4 g m2 (continuous infusion), cyclophosphamide 7.2 g m-2 and carboplatin 0.8 g m-2 (Regimen 2) followed by infusion of previously stored autologous marrow. Regimen 1 was associated with considerable renal toxicity and mucositis, whereas Regimen 2 was relatively well tolerated. Two patients died as a consequence of the treatment: one of candidemia and one of interstitial pulmonary fibrosis. Only one of 17 patients who were autografted in or approaching marker remission subsequently developed disease progression (event-free survival 82%, 95% confidence interval [CI] 55% to 94%), whereas all four patients who had progressive disease at autografting subsequently developed further disease progression and died. Fourteen patients remain well and free of disease 0.5 to 6.5 years (median 3.3) post-BMT (event-free survival 67%, 95% CI 43% to 83%). A strategy of prompt reinduction followed by high-dose chemotherapy and autologous BMT at the first sign of failure of standard therapy may allow cure to be a realistic expectation.

Full text

PDF
597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bearman S. I., Appelbaum F. R., Buckner C. D., Petersen F. B., Fisher L. D., Clift R. A., Thomas E. D. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988 Oct;6(10):1562–1568. doi: 10.1200/JCO.1988.6.10.1562. [DOI] [PubMed] [Google Scholar]
  2. Birch R., Williams S., Cone A., Einhorn L., Roark P., Turner S., Greco F. A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986 Mar;4(3):400–407. doi: 10.1200/JCO.1986.4.3.400. [DOI] [PubMed] [Google Scholar]
  3. Blijham G., Spitzer G., Litam J., Zander A. R., Verma D. S., Vellekoop L., Samuels M. L., McCredie K. B., Dicke K. A. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer. 1981 Apr;17(4):433–441. doi: 10.1016/0014-2964(81)90252-8. [DOI] [PubMed] [Google Scholar]
  4. Broun E. R., Nichols C. R., Einhorn L. H., Tricot G. J. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer. 1991 Oct 1;68(7):1513–1515. doi: 10.1002/1097-0142(19911001)68:7<1513::aid-cncr2820680708>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  5. Broun E. R., Nichols C. R., Kneebone P., Williams S. D., Loehrer P. J., Einhorn L. H., Tricot G. J. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med. 1992 Jul 15;117(2):124–128. doi: 10.7326/0003-4819-117-2-124. [DOI] [PubMed] [Google Scholar]
  6. Broun E. R., Nichols C. R., Tricot G., Loehrer P. J., Williams S. D., Einhorn L. H. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant. 1991 Jan;7(1):53–56. [PubMed] [Google Scholar]
  7. Buckner C. D., Clift R. A., Fefer A., Funk D. D., Glucksberg H., Neiman P. E., Paulsen A., Storb R., Thomas E. D. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):709–714. [PubMed] [Google Scholar]
  8. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  9. Cheson B. D., Lacerna L., Leyland-Jones B., Sarosy G., Wittes R. E. Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med. 1989 Jan 1;110(1):51–65. doi: 10.7326/0003-4819-110-1-51. [DOI] [PubMed] [Google Scholar]
  10. Droz J. P., Pico J. L., Ghosn M., Gouyette A., Baume D., Piot G., Ostronoff M., Theodore C., Beaujean F., Hayat M. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer. 1991;27(7):831–835. doi: 10.1016/0277-5379(91)90127-y. [DOI] [PubMed] [Google Scholar]
  11. Einhorn L. H. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990 Nov;8(11):1777–1781. doi: 10.1200/JCO.1990.8.11.1777. [DOI] [PubMed] [Google Scholar]
  12. Elias A. D., Eder J. P., Shea T., Begg C. B., Frei E., 3rd, Antman K. H. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol. 1990 Jan;8(1):170–178. doi: 10.1200/JCO.1990.8.1.170. [DOI] [PubMed] [Google Scholar]
  13. Feuer E. J., Kessler L. G., Baker S. G., Triolo H. E., Green D. T. The impact of breakthrough clinical trials on survival in population based tumor registries. J Clin Epidemiol. 1991;44(2):141–153. doi: 10.1016/0895-4356(91)90262-8. [DOI] [PubMed] [Google Scholar]
  14. Harland S. J., Newell D. R., Siddik Z. H., Chadwick R., Calvert A. H., Harrap K. R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44(4):1693–1697. [PubMed] [Google Scholar]
  15. Harstrick A., Schmoll H. J., Wilke H., Köhne-Wömpner C. H., Stahl M., Schöber C., Casper J., Bruderek L., Schmoll E., Bokemeyer C. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol. 1991 Sep;9(9):1549–1555. doi: 10.1200/JCO.1991.9.9.1549. [DOI] [PubMed] [Google Scholar]
  16. Herzig G. P. Autologous marrow transplantation in cancer therapy. Prog Hematol. 1981;12:1–23. [PubMed] [Google Scholar]
  17. Loehrer P. J., Sr, Einhorn L. H., Williams S. D. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol. 1986 Apr;4(4):528–536. doi: 10.1200/JCO.1986.4.4.528. [DOI] [PubMed] [Google Scholar]
  18. Loehrer P. J., Sr, Lauer R., Roth B. J., Williams S. D., Kalasinski L. A., Einhorn L. H. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988 Oct 1;109(7):540–546. doi: 10.7326/0003-4819-109-7-540. [DOI] [PubMed] [Google Scholar]
  19. Motzer R. J., Gulati S. C., Crown J. P., Weisen S., Doherty M., Herr H., Fair W., Sheinfeld J., Sogani P., Russo P. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer. 1992 Jan 15;69(2):550–556. doi: 10.1002/1097-0142(19920115)69:2<550::aid-cncr2820690245>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  20. Mulder P. O., de Vries E. G., Koops H. S., Splinter T., Maas A., van der Geest S., Mulder N. H., Sleijfer D. T. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol. 1988 Apr;24(4):675–679. doi: 10.1016/0277-5379(88)90298-2. [DOI] [PubMed] [Google Scholar]
  21. Nichols C. R., Andersen J., Lazarus H. M., Fisher H., Greer J., Stadtmauer E. A., Loehrer P. J., Trump D. L. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992 Apr;10(4):558–563. doi: 10.1200/JCO.1992.10.4.558. [DOI] [PubMed] [Google Scholar]
  22. Nichols C. R., Tricot G., Williams S. D., van Besien K., Loehrer P. J., Roth B. J., Akard L., Hoffman R., Goulet R., Wolff S. N. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989 Jul;7(7):932–939. doi: 10.1200/JCO.1989.7.7.932. [DOI] [PubMed] [Google Scholar]
  23. Reece D. E., Barnett M. J., Connors J. M., Fairey R. N., Fay J. W., Greer J. P., Herzig G. P., Herzig R. H., Klingemann H. G., LeMaistre C. F. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1991 Oct;9(10):1871–1879. doi: 10.1200/JCO.1991.9.10.1871. [DOI] [PubMed] [Google Scholar]
  24. Rosti G., Albertazzi L., Salvioni R., Pizzocaro G., Cetto G. L., Bassetto M. A., Marangolo M. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol. 1992 Dec;3(10):809–812. doi: 10.1093/oxfordjournals.annonc.a058100. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES